Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Identify first generic entrants
  • Uncover prior art in abandoned patent applications and expired patents

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

Details for Patent: 8,067,427

« Back to Dashboard

Which drugs does patent 8,067,427 protect, and when does it expire?

Patent 8,067,427 protects CAPRELSA and is included in one NDA.

This patent has thirty-two patent family members in thirty countries.

Summary for Patent: 8,067,427

Title:Pharmaceutical compositions comprising ZD6474
Abstract: A pharmaceutical composition comprising ZD6474 or a pharmaceutically acceptable salt thereof, a brittle diluent and a second diluent which is practically insoluble and has ductile compression properties.
Inventor(s): Stott; Paul William (Wilmington, DE)
Assignee: AstraZeneca AB (Sodertajle, SE)
Application Number:11/596,979
Patent Claim Types:
see list of patent claims
Composition; Compound;

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Genzyme Corp
TABLET;ORAL022405-001Apr 6, 2011RXYesNo8,067,427► SubscribeY
Genzyme Corp
TABLET;ORAL022405-002Apr 6, 2011RXYesYes8,067,427► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,067,427

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0411378.3May 21, 2004
PCT Information
PCT FiledMay 18, 2005PCT Application Number:PCT/GB2005/001931
PCT Publication Date:December 01, 2005PCT Publication Number: WO2005/112934

International Patent Family for Patent: 8,067,427

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office1753431► Subscribe
Spain2330025► Subscribe
Cyprus1109500► Subscribe
Germany602005016105► Subscribe
Denmark1753431► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.